文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植后1年T细胞受体多样性遗传学研究

Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Leukemia · 2019-11-26

该研究对116例移植后1年完全供者嵌合受者及其供者移植前样本行TCR CDR3β免疫测序,发现移植前后免疫组库重叠极小,支持各年龄均以从头重建为主;受者/供者年龄增大及CMV血清学阳性合并感染/再激活与1年时多样性降低显著相关;除CMV感染/再激活外,TCR多样性不能预测GVHD、复发、死亡或感染。

要点

  • 移植前后TCR组库重叠极小,支持各年龄均以从头重建为主。
  • 受者/供者年龄增大及CMV血清学阳性合并感染/再激活与1年时多样性降低显著相关。
  • 除CMV感染/再激活外,TCR多样性不能预测GVHD、复发、死亡或感染。

核心结论

  • 异基因HSCT后1年T细胞组库以从头重建为主,供受者年龄和CMV状态影响多样性。

研究设计与样本

  • 对116例移植后1年完全供者嵌合受者及其供者移植前样本行TCR CDR3β免疫测序。

主要发现

  • 移植前后组库重叠极小,支持各年龄均以从头重建为主。
  • 受者/供者年龄增大及CMV血清学阳性合并感染/再激活与1年时多样性降低显著相关。
  • CMV特异性T细胞克隆影响组库克隆性,并伴随有限数量非CMV T细胞群体扩增。
  • 除CMV感染/再激活外,TCR多样性不能预测GVHD、复发、死亡或感染。

临床怎么用

  • 供者选择及CMV血清学/感染状态或可纳入优化免疫重建的考量。
  • 1年时TCR多样性不宜单独用于预测GVHD、复发、死亡或感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

After allogeneic hematopoietic stem cell transplantation (HSCT), immune reconstitution leads to the development of a new T-cell repertoire. Immune reconstitution could be influenced by events such as conditioning, infections, and graft versus host disease (GVHD). Factors influencing the TCR diversity are of great interest to fine-tune the strategy for donor selection and to optimize standard of care. In this work, immunosequencing of the TCR CDR3β region was carried out in a large cohort of 116 full chimeric recipients at 1 year post-HSCT and their respective donors prior to transplantation. The repertoire overlap before and after HSCT was minimal, supporting de novo reconstitution as a primary pathway at any age. Among the parameters investigated, increased patient and/or donor age as well as positive CMV serologic status reinforced by CMV infection/reactivation were the ones significantly associated with a reduced diversity at 1 year post-HSCT. CMV-specific T-cell clones were shown to influence the clonality of the repertoire alongside the expansion of limited numbers of non-CMV T-cell populations. Interestingly, at the exception of CMV infection/reactivation, TCR diversity was not predictive of GVHD, relapse, death, or infections post-HSCT.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Buhler S, Bettens F, Dantin C, et al. Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation. Leukemia. 2019. PMID: 31772297. doi:10.1038/s41375-019-0654-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。